Disclosed are methods for forming shear-thinning fluid gel compositions comprising a microgel particle-forming polymer dispersed in an aqueous medium. The viscosity of the fluid gel compositions reduces when the gel is exposed to shear. Also disclosed are shear-thinning fluid gel compositions obtained by such methods, and medical uses of such compositions.

Disclosed are methods for forming shear-thinning fluid gel compositions comprising a microgel particle-forming polymer dispersed in an aqueous medium. The viscosity of the fluid gel compositions reduces when the gel is exposed to shear. Also disclosed are shear-thinning fluid gel compositions obtained by such methods, and medical uses of such compositions.

Methods for treating pruritis in humans and animals using topically administrable compositions containing olopatadine are disclosed. The compositions quickly relieve itchy skin.

Methods for treating pruritis in humans and animals using topically administrable compositions containing olopatadine are disclosed. The compositions quickly relieve itchy skin.

The described invention provides a method of treating localized pain comprising (a) applying topically to an area of skin of a subject overlaying the localized pain a pharmaceutical composition comprising a cannabinoid component and a chemical driver component comprising two or more of methylsulfonylmethane (MSM), and ethoxydiglycol, and propylene glycol; and applying an external energy effective to enhance transdermal permeation of the pharmaceutical composition into the skin. wherein the components of the composition and the device are cooperatively effective to work together to maximize transdermal delivery of the composition, deeply penetrate the skin of the subject and to provide pain relief.

To develop a universal and long-lasting influenza or other pathogens vaccine has been a mission impossible goal in the life science and health field. Applicants disclose, herein, vaccines prepared against SARS-COV-2, an influenza A strain vaccine prepared from a 1934 influenza virus (A/PR/8/34 H1N1, Puerto Roca, 1934), and an influenza B strain vaccine prepared from a 1940 influenza virus. The disclosed vaccine induces production of broadly neutralizing antibodies in mice. The presently disclosed vaccine is able to inhibit two other influenza A strains: a 2009 influenza H1N1 virus collected from Los Angeles (A/California/07/2009) and a 2014 influenza H3N2 virus collected from Hong Kong (A/Hongkong/4801/2014). Applicants also describe an influenza B strain vaccine prepared from a B strain virus from a 1940 patient in USA (B/L11/40). The B strain vaccine also produced broadly neutralizing antibodies, in this case against a B strain from Colorado 2017 (B/Colorado/2017). Applicant's methods and compositions are not only useful in creating influenza vaccines with broad activity against other influenza subtypes but also be efficient to generate long-lasting SARS-CoV-2 vaccines against emerging new variants either through recombined protein antigens from SARS-CoV-2 or inactivated SARS-CoV-2 virus.

To develop a universal and long-lasting influenza or other pathogens vaccine has been a mission impossible goal in the life science and health field. Applicants disclose, herein, vaccines prepared against SARS-COV-2, an influenza A strain vaccine prepared from a 1934 influenza virus (A/PR/8/34 H1N1, Puerto Roca, 1934), and an influenza B strain vaccine prepared from a 1940 influenza virus. The disclosed vaccine induces production of broadly neutralizing antibodies in mice. The presently disclosed vaccine is able to inhibit two other influenza A strains: a 2009 influenza H1N1 virus collected from Los Angeles (A/California/07/2009) and a 2014 influenza H3N2 virus collected from Hong Kong (A/Hongkong/4801/2014). Applicants also describe an influenza B strain vaccine prepared from a B strain virus from a 1940 patient in USA (B/L11/40). The B strain vaccine also produced broadly neutralizing antibodies, in this case against a B strain from Colorado 2017 (B/Colorado/2017). Applicant's methods and compositions are not only useful in creating influenza vaccines with broad activity against other influenza subtypes but also be efficient to generate long-lasting SARS-CoV-2 vaccines against emerging new variants either through recombined protein antigens from SARS-CoV-2 or inactivated SARS-CoV-2 virus.

The present invention relates to a kit, comprising at least one cold spray and at least one dosage form for transdermally administering at least one pharmaceutically active ingredient, to said kit for use in the treatment of a patient, to the use of a cold spray in order to shorten the resorption delay time in the application of a dosage form for transdermally administering at least one pharmaceutically active ingredient, and to a method for treating a patient.

A composition for restoring or increasing tissue perfusion is provided. The composition includes polyethylene glycol polymers (PEG) with a molecular weight of 18,000-100,000 Da at a concentration of 5-20% by weight; PEG with a molecular weight of 1,000-10,000 Da at a concentration of 1-30% by weight; and water, wherein said PEG with a molecular weight of 18,000-100,000 Da and said PEG with a molecular weight of 1,000-10,000 Da are dissolved or dispersed in said water.

A composition for restoring or increasing tissue perfusion is provided. The composition includes polyethylene glycol polymers (PEG) with a molecular weight of 18,000-100,000 Da at a concentration of 5-20% by weight; PEG with a molecular weight of 1,000-10,000 Da at a concentration of 1-30% by weight; and water, wherein said PEG with a molecular weight of 18,000-100,000 Da and said PEG with a molecular weight of 1,000-10,000 Da are dissolved or dispersed in said water.